Riboway Therapeutics
Riboway Therapeutics applies AI to RNA biology to open new protein targets and druggable pathways. It uses smart RNA-targeting technology to control protein expression and function—upregulating, downregulating, activating, or inhibiting proteins as needed. The company operates in B2B biotech, collaborating with pharmaceutical developers and research institutions. Its core tech combines AI-driven discovery with RNA biology to identify and modulate RNA-based targets. The aim is to broaden the range of druggable targets and scale RNA-targeted therapies for diverse diseases.
Riboway Therapeutics
Riboway Therapeutics applies AI to RNA biology to open new protein targets and druggable pathways. It uses smart RNA-targeting technology to control protein expression and function—upregulating, downregulating, activating, or inhibiting proteins as needed. The company operates in B2B biotech, collaborating with pharmaceutical developers and research institutions. Its core tech combines AI-driven discovery with RNA biology to identify and modulate RNA-based targets. The aim is to broaden the range of druggable targets and scale RNA-targeted therapies for diverse diseases.